Atallah EL - Search Results

1

Chronic Myeloid Leukemia: Part I-Real-World Treatment Patterns, Healthcare Resource Utilization, and Associated Costs in Later Lines of Therapy in the United States.

Atallah EL, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A, Wu EQ, Patwardhan P. Atallah EL, et al. J Health Econ Outcomes Res. 2022 Aug 4;9(2):19-29. doi: 10.36469/001c.36975. eCollection 2022. J Health Econ Outcomes Res. 2022. PMID: 35979528 Free PMC article.

2

Tyrosine kinase inhibitor therapy treatment and discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States: a clinical practice perspective.

Ritchie EK, Latremouille-Viau D, Guerin A, Pivneva I, Habucky K, Ndife B, Joseph GJ, Atallah EL. Ritchie EK, et al. Among authors: atallah el. Leuk Lymphoma. 2019 Jun;60(6):1476-1484. doi: 10.1080/10428194.2018.1538510. Epub 2019 Jan 22. Leuk Lymphoma. 2019. PMID: 30668234

3

Tyrosine kinase inhibitor therapy discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States after clinical practice guideline updates.

Atallah EL, Sadek I, Maegawa R, Cao X, Latremouille-Viau D, Pivneva I, Rossi C, Guerin A, Kota V. Atallah EL, et al. Leuk Lymphoma. 2021 Jul;62(7):1730-1739. doi: 10.1080/10428194.2021.1885656. Epub 2021 Mar 1. Leuk Lymphoma. 2021. PMID: 33648418

4

Chronic Myeloid Leukemia: Part II-Cost of Care Among Patients in Advanced Phases or Later Lines of Therapy in Chronic Phase in the United States from a Commercial Perspective.

Atallah EL, Maegawa R, Latremouille-Viau D, Rossi C, Guérin A. Atallah EL, et al. J Health Econ Outcomes Res. 2022 Aug 4;9(2):30-36. doi: 10.36469/001c.36976. eCollection 2022. J Health Econ Outcomes Res. 2022. PMID: 35979529 Free PMC article.

5

Therapy for patients with chronic phase-chronic myeloid leukemia previously treated with ⩾2 tyrosine kinase inhibitors: a systematic literature review.

Atallah E, Saini L, Maegawa R, Rajput T, Corbin R, Viana R. Atallah E, et al. Ther Adv Hematol. 2023 Dec 14;14:20406207221150305. doi: 10.1177/20406207221150305. eCollection 2023. Ther Adv Hematol. 2023. PMID: 38105770 Free PMC article. Review.

6

Venetoclax-based Treatment as Frontline Therapy for Chronic Lymphocytic Leukemia.

Guru Murthy GS, Atallah E. Guru Murthy GS, et al. Hematol Oncol Stem Cell Ther. 2023 May 23;16(4):346-350. doi: 10.56875/2589-0646.1039. Hematol Oncol Stem Cell Ther. 2023. PMID: 37363977 Review.

7

Real-world Management of CML: Outcomes and Treatment Patterns.

Held N, Atallah EL. Held N, et al. Among authors: atallah el. Curr Hematol Malig Rep. 2023 Oct;18(5):167-175. doi: 10.1007/s11899-023-00703-w. Epub 2023 Jul 3. Curr Hematol Malig Rep. 2023. PMID: 37395944 Review.

8

Dasatinib dose management for the treatment of chronic myeloid leukemia.

Talpaz M, Saglio G, Atallah E, Rousselot P. Talpaz M, et al. Cancer. 2018 Apr 15;124(8):1660-1672. doi: 10.1002/cncr.31232. Epub 2018 Jan 25. Cancer. 2018. PMID: 29370463 Free PMC article. Review.

9

Incidence and survival of therapy related myeloid neoplasm in United States.

Guru Murthy GS, Hamadani M, Dhakal B, Hari P, Atallah E. Guru Murthy GS, et al. Leuk Res. 2018 Aug;71:95-99. doi: 10.1016/j.leukres.2018.07.013. Epub 2018 Jul 23. Leuk Res. 2018. PMID: 30048839

10

Amebic Encephalitis in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib Therapy.

Voshtina E, Huang H, Raj R, Atallah E. Voshtina E, et al. Case Rep Hematol. 2018 Aug 1;2018:6514604. doi: 10.1155/2018/6514604. eCollection 2018. Case Rep Hematol. 2018. PMID: 30155323 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

117 results

Search Page

Filters